{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:12:56Z","timestamp":1791972776074,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T00:00:00Z","timestamp":1531785600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2782-5","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T08:52:38Z","timestamp":1531817558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"19","author":[{"given":"James X.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Paul","family":"Wileyto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8136-2123","authenticated-orcid":false,"given":"Michael C.","family":"Soulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,17]]},"reference":[{"key":"2782_CR1","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063\u201372.","journal-title":"J Clin Oncol"},{"key":"2782_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S1072-7515(00)00222-2","volume":"190","author":"RS Chamberlain","year":"2000","unstructured":"Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432\u201345.","journal-title":"J Am Coll Surg"},{"key":"2782_CR3","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00259-015-3264-6","volume":"43","author":"CE Barbier","year":"2016","unstructured":"Barbier CE, Garske-Roman U, Sandstrom M, Nyman R, Granberg D. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging. 2016;43:1425\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"2782_CR4","doi-asserted-by":"publisher","first-page":"S286","DOI":"10.1007\/s12032-010-9750-6","volume":"28","author":"XD Dong","year":"2011","unstructured":"Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol. 2011;28(Suppl 1):S286\u201390.","journal-title":"Med Oncol"},{"key":"2782_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12020-013-0130-9","volume":"47","author":"F Fiore","year":"2014","unstructured":"Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, Di Sarno A, Carratu AC, de Luca di Roseto C, Colao A, Faggiano A. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47:177\u201382.","journal-title":"Endocrine"},{"key":"2782_CR6","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/cncr.21389","volume":"104","author":"S Gupta","year":"2005","unstructured":"Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590\u2013602.","journal-title":"Cancer"},{"key":"2782_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11864-012-0200-x","volume":"13","author":"K Memon","year":"2012","unstructured":"Memon K, Lewandowski RJ, Riaz A, Salem R. Chemoembolization and radioembolization for metastatic disease to the liver: available data and future studies. Curr Treat Options in Oncol. 2012;13:403\u201315.","journal-title":"Curr Treat Options in Oncol"},{"key":"2782_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/ajco.12438","volume":"12","author":"M Pericleous","year":"2016","unstructured":"Pericleous M, Caplin ME, Tsochatzis E, Yu D, Morgan-Rowe L, Toumpanakis C. Hepatic artery embolization in advanced neuroendocrine tumors: efficacy and long-term outcomes. Asia Pac J Clin Oncol. 2016;12:61\u20139.","journal-title":"Asia Pac J Clin Oncol"},{"key":"2782_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jvir.2007.04.018","volume":"18","author":"AT Ruutiainen","year":"2007","unstructured":"Ruutiainen AT, Soulen MC, Tuite CM, Clark TW, Mondschein JI, Stavropoulos SW, Trerotola SO. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol. 2007;18:847\u201355.","journal-title":"J Vasc Interv Radiol"},{"key":"2782_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jvir.2013.09.013","volume":"25","author":"CT Sofocleous","year":"2014","unstructured":"Sofocleous CT, Petre EN, Gonen M, Reidy-Lagunes D, Ip IK, Alago W, Covey AM, Erinjeri JP, Brody LA, Maybody M, et al. Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases. J Vasc Interv Radiol. 2014;25:22\u201330. quiz 31","journal-title":"J Vasc Interv Radiol"},{"key":"2782_CR11","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1007\/s00330-013-2925-8","volume":"23","author":"WH Sommer","year":"2013","unstructured":"Sommer WH, Ceelen F, Garcia-Albeniz X, Paprottka PM, Auernhammer CJ, Armbruster M, Nikolaou K, Haug AR, Reiser MF, Theisen D. Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Eur Radiol. 2013;23:3094\u2013103.","journal-title":"Eur Radiol"},{"key":"2782_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/107327480601300110","volume":"13","author":"JR Strosberg","year":"2006","unstructured":"Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006;13:72\u20138.","journal-title":"Cancer Control"},{"key":"2782_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00270-012-0424-y","volume":"36","author":"N Bhagat","year":"2013","unstructured":"Bhagat N, Reyes DK, Lin M, Kamel I, Pawlik TM, Frangakis C, Geschwind JF. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol. 2013;36:449\u201359.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2782_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","volume":"39","author":"JP Boudreaux","year":"2010","unstructured":"Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, Yao JC, North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39:753\u201366.","journal-title":"Pancreas"},{"key":"2782_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/hpb.12326","volume":"17","author":"A Kennedy","year":"2015","unstructured":"Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P, NET-Liver-Metastases Consensus Conference. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford). 2015;17:29\u201337.","journal-title":"HPB (Oxford)"},{"key":"2782_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","volume":"39","author":"MH Kulke","year":"2010","unstructured":"Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39:735\u201352.","journal-title":"Pancreas"},{"key":"2782_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.6004\/jnccn.2015.0011","volume":"13","author":"MH Kulke","year":"2015","unstructured":"Kulke MH, Shah MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw. 2015;13:78\u2013108.","journal-title":"J Natl Compr Cancer Netw"},{"key":"2782_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000335597","volume":"95","author":"M Pavel","year":"2012","unstructured":"Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, Anlauf M, Wiedenmann B, Salazar R, Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157\u201376.","journal-title":"Neuroendocrinology"},{"key":"2782_CR19","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s11605-008-0640-6","volume":"12","author":"SC Pitt","year":"2008","unstructured":"Pitt SC, Knuth J, Keily JM, McDermott JC, Weber SM, Chen H, Rilling WS, Quebbeman EJ, Agarwal DM, Pitt HA. Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg. 2008;12:1951\u201360.","journal-title":"J Gastrointest Surg"},{"key":"2782_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000336941","volume":"96","author":"F Maire","year":"2012","unstructured":"Maire F, Lombard-Bohas C, O\u2019Toole D, Vullierme MP, Rebours V, Couvelard A, Pelletier AL, Zappa M, Pilleul F, Hentic O, et al. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology. 2012;96:294\u2013300.","journal-title":"Neuroendocrinology"},{"key":"2782_CR21","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.2214\/AJR.06.0933","volume":"188","author":"AS Ho","year":"2007","unstructured":"Ho AS, Picus J, Darcy MD, Tan B, Gould JE, Pilgram TK, Brown DB. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol. 2007;188:1201\u20137.","journal-title":"AJR Am J Roentgenol"},{"key":"2782_CR22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jhep.2011.09.012","volume":"56","author":"B Guiu","year":"2012","unstructured":"Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V, Malka D, Leboulleux S, Ducreux M, Schlumberger M, et al. Liver\/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol. 2012;56:609\u201317.","journal-title":"J Hepatol"},{"key":"2782_CR23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.2214\/AJR.11.7066","volume":"198","author":"RC Gaba","year":"2012","unstructured":"Gaba RC. Chemoembolization practice patterns and technical methods among interventional radiologists: results of an online survey. AJR Am J Roentgenol. 2012;198:692\u20139.","journal-title":"AJR Am J Roentgenol"},{"key":"2782_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ecl.2010.12.008","volume":"40","author":"E Vinik","year":"2011","unstructured":"Vinik E, Silva MP, Vinik AI. Measuring the relationship of quality of life and health status, including tumor burden, symptoms, and biochemical measures in patients with neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40:97\u2013109. viii","journal-title":"Endocrinol Metab Clin N Am"},{"key":"2782_CR25","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jvir.2017.04.025","volume":"28","author":"RC Gaba","year":"2017","unstructured":"Gaba RC, Lokken RP, Hickey RM, Lipnik AJ, Lewandowski RJ, Salem R, Brown DB, Walker TG, Silberzweig JE, Baerlocher MO, et al. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. J Vasc Interv Radiol. 2017;28:1210\u20131223.e3.","journal-title":"J Vasc Interv Radiol"},{"key":"2782_CR26","first-page":"155","volume-title":"Phase II selection designs. In Crowley J, Ankerst DP, editors. Handbook of statistics in clinical oncology","author":"PY Liu","year":"2006","unstructured":"Liu PY, Moon J, LeBlanc M. Phase II selection designs. In Crowley J, Ankerst DP, editors. Handbook of statistics in clinical oncology. 2nd ed. Boca Raton, FL: Chapman & Hall\/CRC; 2006. p. 155\u201366.","edition":"2"},{"key":"2782_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2307\/2532552","volume":"49","author":"P Liu","year":"1993","unstructured":"Liu P, Dahlberg S, Crowley J. Selection designs for pilot studies based on survival. Biometrics. 1993;49:391\u20138.","journal-title":"Biometrics"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2782-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2782-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2782-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T19:05:20Z","timestamp":1563303920000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2782-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,17]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2782"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2782-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,17]]},"assertion":[{"value":"8 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the University of Pennsylvania Institutional Review Board (IRB) and the IRB or corresponding ethics committee at each participating site.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MCS has received research funding from Guerbet LLC and BTG international and is a consultant for Guerbet LLC, Merit Medical, Terumo Medical, and Bayer\/Onyx.The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"390"}}